🔗 Share this article

Given that the United States continues making historic adjustments to its vaccination schedules, a particular individual appears in a surprising turn: Høeg, an American of Danish descent sports physician and epidemiologist who first made her name by casting doubt on Covid vaccines during the pandemic and has focused upon alleged deaths following COVID-19 vaccination in her recent position at the US Food and Drug Administration (FDA).

Proposed Changes to Childhood Immunization Program

Agency leaders planned to unveil sweeping revisions to the pediatric vaccine schedule earlier this month, bringing the US with the Danish vaccine program, sources say – a substantial departure that would put the US at odds with much of the global community with insufficient data for public health gain. This reveal has been postponed until the coming year.

Rather than the director of the vaccine center, Dr. Høeg is set to present at the gathering. She was newly appointed interim head of the FDA’s CDER, the fifth individual to run the division this year.

A Shift at the Agency

The acting appointment might represent a tighter collaboration between the drug and biologics centers as Høeg and Prasad consolidate power at the agency – and it suggests a increased emphasis upon reevaluating previously authorized immunizations at the FDA.

Dr. Høeg has repeatedly called for discontinuing specific childhood immunization guidelines in the US to become more similar to Denmark, a society with nationalized medicine and a citizenry approximately the size of Wisconsin’s.

To date comments, she has persisted in emphasizing on vaccines – usually the responsibility of Dr. Prasad, head of the FDA’s vaccine center – instead of pharmaceutical oversight.

Doubts Over Expertise

Dr. Høeg has little discernible background in drug development, regulation or administrative roles, which has been standard for past heads of the biologics center. She has served at the FDA as a senior adviser to the agency head and CBER since March.

“She doesn’t seem to have any of the qualifications” for leading the pharmaceutical oversight division, said Dr. Jonathan Howard. “She has not conducted a clinical trial. She has no expertise in managing a large organization. She lacks background in pharmaceutical oversight.”

Previous directors of the center would “be deeply familiar with laws and regulations and the research of drug development”, commented Dr. Janet Woodcock. “Clearly, she lacks the type of experience that previous people who ran CBER have had.”

This division has an immense portfolio at the FDA, the former commissioner stated.

“The public just focuses on the new drug program, but the generic drug division authorizes a multitude of off-brand pharmaceuticals. There’s a biosimilars program, non-prescription drug unit and more, and all of those must be managed,” she explained. “The responsibility you neglect, that is the part that I always told people is going to cause problems.”

Additionally, a substantial administrative element to the job, which supervises more than 5,000 employees. “It is a huge management job, if you execute it properly,” Woodcock added.

Official Statement and Disputed Policies

When asked about concerns about Høeg’s credentials and whether this selection signifies increased cooperation among FDA leaders on immunizations, a representative responded that the “concerns stem from inaccurate premises”.

“Her resume matches the responsibilities of her job,” the spokesperson said, citing the period Høeg spent counseling the agency head on “pharmaceutical safety and regulatory science, including computerized risk analysis and shot safety tracking”.

In her interim role, Høeg inherits the agency head's controversial expedited review system, a contentious one-day drug-approval program that reportedly troubled her preceding directors. “By what process are these drugs being selected for this voucher program? Who takes the choices?” Dr. Howard questioned. “There’s a lot of lack of transparency happening at the regulatory body right now.”

Overall, he stated, “the agency seems to be moving towards more relaxed rules of all drugs, with the exception of vaccines.”

Public History on Vaccines

Regarding vaccines, Dr. Høeg has a more documented, if problematic, track record, critics observe. She authored a study using unverified crowd-sourced reports to estimate the rate of heart inflammation following Covid immunization. She counseled the Florida chief medical officer Joseph Ladapo, who allegedly have changed statistics to suggest Covid vaccines are riskier than they are.

Included in her “desired changes” for the new government included revising guidelines for novel immunizations and halting “optional” immunizations, she said after the election on a online show. At the agency, Dr. Høeg has reportedly floated the idea of preventing young men from obtaining Covid vaccinations.

“She’s an all-around ideologue who starts off with her conclusions and tailors the evidence to accommodate the data in a highly deceptive, untruthful fashion,” Dr. Howard said.

Taking Control and a “Push for Payback”

Dr. Høeg became part of other skeptics, {like|